First-Line Pharmacologic Interventions for Common Conditions
Acute Pain
For mild to moderate acute pain, initiate acetaminophen (up to 4g/24 hours) or an NSAID as first-line therapy, with the choice depending on pain type and patient risk factors for NSAID-related adverse effects. 1 For severe acute pain, potent opioids are appropriate, though caution is warranted given misuse potential even for short-term use. If first-line agents prove insufficient for mild-to-moderate pain, acetaminophen/opioid combinations targeting separate pathways are reasonable second-line options 1.
Common pitfall: Failing to assess total acetaminophen intake from all sources before prescribing additional doses—patients often underestimate their current consumption.
Bacterial Infection
Evidence provided does not address bacterial infection treatment—this requires condition-specific antibiotic selection based on likely pathogens, local resistance patterns, and infection site.
Hypertension
Uncomplicated Hypertension (Diastolic and/or Systolic)
Initiate monotherapy with a thiazide/thiazide-like diuretic (Grade A), long-acting calcium channel blocker (Grade B), ACE inhibitor in non-Black patients (Grade B), or ARB (Grade B). 2 Beta-blockers are NOT recommended as first-line in patients ≥60 years old (Grade A), and alpha-blockers are NOT recommended as first-line agents for uncomplicated hypertension (Grade A) 2.
For Stage 2 hypertension (SBP ≥140 mmHg and DBP ≥90 mmHg), initiate combination therapy with two first-line agents of different classes, ideally as a single-pill combination to improve adherence and BP control. 3 This approach is particularly important when SBP is ≥20 mmHg above target or DBP is ≥10 mmHg above target, though exercise caution in elderly or frail patients where substantial BP drops may be poorly tolerated 2.
Isolated Systolic Hypertension
Begin with thiazide/thiazide-like diuretic (Grade A), long-acting dihydropyridine calcium channel blocker (Grade A), or ARB (Grade B). 2 Avoid hypokalemia with thiazide monotherapy (Grade C).
Key Combination Principles
- Useful combinations: thiazide/thiazide-like diuretic OR calcium channel blocker WITH ACE inhibitor, ARB, or beta-blocker 2
- DO NOT combine ACE inhibitor with ARB (Grade A)—this increases harm without additional benefit 2, 3
- Avoid combining non-dihydropyridine calcium channel blocker with beta-blocker (Grade D) 2
Critical consideration: Recent 2025 AHA/ACC guidelines emphasize single-pill combinations for Stage 2 hypertension to enhance adherence and reduce cardiovascular events 3.
Type 2 Diabetes with Hypertension
For patients with diabetes and BP ≥130/80 mmHg, treatment depends on albuminuria status:
With albuminuria (UACR ≥30 mg/g): Initiate ACE inhibitor or ARB as first-line therapy (Grade A) to reduce progressive kidney disease risk 4, 5, 6
Without albuminuria and no chronic kidney disease: Choose ACE inhibitor (Grade A for age ≥55), ARB (Grade A with left ventricular hypertrophy and age ≥55), dihydropyridine calcium channel blocker (Grade A for age ≥55), or thiazide-like diuretic (Grade A for age ≥55), with special consideration for ACE inhibitor/ARB given additional renal benefits 4, 5
For BP ≥150/90 mmHg, initiate two antihypertensive medications simultaneously to achieve target BP more effectively 6. Target BP in diabetes is <130/80 mmHg 4, 5, 6.
Important monitoring: Check serum creatinine and potassium 7-14 days after initiating or changing doses of ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists 6.
Hyperlipidemia
Evidence provided does not address lipid management—statin therapy is typically first-line based on cardiovascular risk assessment, though this requires separate guideline review.
Major Depressive Disorder (Acute Phase)
Moderate to Severe MDD
Initiate monotherapy with either cognitive behavioral therapy OR a second-generation antidepressant (strong recommendation; moderate-certainty evidence). 7 Combination therapy with both CBT and a second-generation antidepressant may be considered as initial treatment (conditional recommendation; low-certainty evidence) 7.
The choice between monotherapy options or combination therapy must be personalized based on discussion of benefits, harms, adverse effect profiles, cost, feasibility, specific symptoms (insomnia, hypersomnia, appetite changes), comorbidities, concomitant medications, and patient preferences 7.
Mild MDD
Consider monotherapy with cognitive behavioral therapy as initial treatment (conditional recommendation; low-certainty evidence). 7
Second-Line Treatment (Inadequate Response)
For patients not responding to adequate-dose second-generation antidepressant monotherapy, consider:
- Switching to OR augmenting with cognitive behavioral therapy (conditional recommendation; low-certainty evidence), OR
- Switching to a different second-generation antidepressant OR augmenting with second pharmacologic agent (conditional recommendation; low-certainty evidence) 7
Atrial Fibrillation Stroke Prevention
The evidence provided focuses on rate/rhythm control rather than stroke prevention. For stroke prevention, anticoagulation based on CHA₂DS₂-VASc score is standard—warfarin or direct oral anticoagulants (DOACs) are typically first-line, though this requires dedicated anticoagulation guideline review.
Persistent Asthma
For mild persistent asthma (Step 2 care), initiate low-dose inhaled corticosteroid as preferred first-line controller therapy. 8 Leukotriene receptor antagonists (montelukast, zafirlukast) are alternative but NOT preferred options 8.
For moderate to severe persistent asthma (Step 3+ care in adults/children ≥5 years), combine inhaled corticosteroid with long-acting beta-2 agonist (LABA)—LABA is the PREFERRED adjunctive therapy in patients ≥12 years. 8
Critical safety warning: LABAs must NEVER be used as monotherapy for long-term asthma control 8.
Quick-Relief Medications
Short-acting beta-2 agonists (albuterol, levalbuterol, pirbuterol) are the treatment of choice for acute symptom relief and exercise-induced bronchoconstriction prevention. 8 Increasing SABA use (>2 days/week for symptom relief, excluding EIB prevention) indicates inadequate control requiring initiation or intensification of anti-inflammatory therapy 8.
For moderate-to-severe exacerbations, add systemic corticosteroids to SABA to accelerate recovery and prevent recurrence. 8 Ipratropium bromide provides additive benefit to SABA in emergency settings for moderate/severe exacerbations 8.
Common pitfall: Regular daily chronic use of SABA is NOT recommended—this pattern signals poor asthma control rather than appropriate management 8.